



Leading into SRS 2018, Medicrea Highlights A New Study Showing That Patients Implanted with UNiD™ Patient-Specific Rods are 2.6 times more likely to be optimally corrected.

[This Press Release includes hyperlinks. Click the blue words to access extra content including videos and abstracts.](#)

Lyon and New York, October 10, 2018 - The Medicrea® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTY & MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, announced today the publication of a new study validating the use of UNiD™ Patient-Specific Rods (PSR) for surgical correction of sagittal imbalance in adults.

Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 especially in the USA (+62% cases year-to-date 2018 and +90% in Q3 2018).

Since its inception, the technology has supported surgeons specializing both in adult and pediatric indications with planning services and patient-specific implants focused on restoring sagittal and coronal alignment.

Federico Solla, M.D., Orthopaedic and Scoliosis Surgery Unit, Lenval Hospital, Nice, France and UNiD™ ASI user recently published the [Article](#) titled “*Patient-Specific Rods for Surgical Correction of Sagittal Imbalance in Adults: Technical Aspects and Preliminary Results*”. In this article, Federico Solla emphasizes the expected benefits of patient specific spinal care which include the optimal execution of the plan, decreased mechanical complications, and reduced operating time, no longer requiring the bending of rods during surgery.

This study demonstrates that the use of patient specific rods improves the correspondence between planning and surgical realization.

Evalina Burger, MD, Department of Orthopedics, University of Colorado SOM, Aurora, CO, co-author, stated that “these results support the use of the UNiD™ ASI platform to obtain the expected patient-specific sagittal balance with a special focus on the difference pelvic incidence (PI) – lumbar lordosis (LL).”

Medicrea’s proprietary UNiD™ ASI technology uses Artificial Intelligence that digests scientific data to generate intelligent surgical planning through machine learning while simultaneously allowing the Spine Surgeon to perform detailed, custom analyses of his cases. The entire clinical [workflow is thus managed](#) from start to finish through the UNiD™ comprehensive Platform.

Christopher Kleck, MD, Department of Orthopedics, University of Colorado SOM, Aurora, CO, co-author, added “With its proprietary UNiD™ ASI technology, Medicrea started revolutionizing the spine world by developing a model taking into consideration compensatory mechanisms to individually predict each patient’s outcomes.”

By simulating surgical strategies using proprietary data and algorithms taking into consideration patients’ optimal sagittal alignment and compensatory mechanisms, Medicrea produces a [patient-specific rod](#) industrially bent. This process preserves the rod’s full integrity, and limits stress points that could lead to rod fracture once implanted.

Vincent Fiere, MD, Spinal Unit, Santy Orthopaedic Center and Mermoz Hospital Ramsay GDA, Lyon, France, and co-author, concluded “With Medicrea’s breakthrough technology, we showed that patients implanted with UNiD™ PSRs were 2.6 times more likely to be optimally corrected.”

“We are extremely pleased to see an increasing number of publications focusing on the application of UNiD™ ASI in the treatment of complex spinal deformities” said Denys Sournac, Founder, Chairman and CEO of Medicrea. “A month ago, we concluded the first Artificial Intelligence focused meeting in Lyon with 20 international spine surgeons considered thought-leaders in their field. [Medicrea Artificial Intelligence and Analytics \(MAIA\)](#) was a success. A couple weeks ago, Jean-Luc Clement, MD, Fondation Lenval, Nice, France, published an [Article](#) validating our predictive modelling for AIS patients. Today, we are announcing another publication validating this technology for the adult population. The revolution is only starting, and we are looking forward to the surgeon community embracing the UNiD™ ASI technology to provide their patients with the best possible care.”

[Click here to reach the article: Patient-specific Rods for Surgical Correction of Sagittal Imbalance in Adults: Technical](#)

[Aspects and Preliminary Results - Solla, Federico, MD; Barrey, Cédric Y., MD, PhD; Burger, Evalina, MD; Kleck, Christopher J., MD; Fièrè, Vincent, MD](#)

[Click here to reach the article: Surgical increase in thoracic kyphosis increases unfused lumbar lordosis in selective fusion for thoracic adolescent idiopathic scoliosis - Jean-Luc Clément, MD; Yann Pelletier, MD; Federico Solla, MD; Virginie Rampal, MD](#)

[Click here to reach the video: UCSF Clinical Application: Live Pre-Op Planning with Adaptive Spine Intelligence](#)

[Click here to reach the video: UNiD™ ASI Workflow](#)

[Click here to reach the video: MAIA - Medicea Artificial Intelligence and Analytics - 1st Annual Meeting 2018](#)

About Medicea (www.medicea.com)

Through the lens of predictive medicine, Medicea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a \$10 billion marketplace, Medicea is a Small and Medium sized Enterprise (SME) with 210 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.

For further information, please visit: Medicea.com.

Connect with Medicea

[FACEBOOK](#) | [INSTAGRAM](#) | [TWITTER](#) | [WEBSITE](#) | [YOUTUBE](#)

Medicea

Denys SOURNAC
Founder, Chairman and CEO
dsournac@medicea.com

Fabrice KILFIGER
Chief Financial Officer
fkilfiger@medicea.com
Tel: +33 (0)4 72 01 87 87

Medicea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED
LEI: 969500BR1CPTYMTJBA37



Medicea is traded on
OTCQX Best Market
Tickers: MRNTY & MRNTF

